Barbara S. Gillespie
Plenary Session 8 presentation title: “How has COVID-19 changed our views on delivering clinical trials?”
Barbara S. Gillespie, MD, MMS, FASN
Vice President, Therapeutic Head of Nephrology, Covance
Adjunct Professor, University of North Carolina, Division of Nephrology & Hypertension
Dr. Gillespie is a board-certified nephrologist who has been supporting sponsors on renal drug & device development for the past 15+ years. She serves on the Board of Directors at the Kidney Health Initiative, a public-private partnership between the FDA and American Society of Nephrology. The mission of KHI is to collaborate with stakeholders to catalyze innovative and patient-centric clinical development. She co-authored the publication “Surrogate Endpoints in IgAN” (2019) and continues to serve on similar workgroups for FSGS and C3G. Dr. Gillespie completed her residency in internal medicine at the University of North Carolina and her nephrology fellowship at Duke University Medical Center. She serves on multiple Stakeholder, Advisory Boards, Steering Committees (e.g. National Kidney Foundation Patient Registry, NKF/FDA Scientific Workshops (2020, 2018), CardioRenal Society of America Board of Directors, NephCure Clinical Trial Collaborative, PCORI, SONG, etc) and as an invited faculty speaker at several global Nephrology Conferences.